Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
10.13
+0.48 (4.97%)
Nov 22, 2024, 4:00 PM EST - Market closed

Avalo Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Nov '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Market Capitalization
1067471914,21218,865
Upgrade
Market Cap Growth
418.10%-84.63%-75.15%-95.47%-77.67%14214.17%
Upgrade
Enterprise Value
27-1521534,18018,877
Upgrade
Last Close Price
10.139.101209.614895.967603.1415523.08
Upgrade
PS Ratio
25.573.792.6335.37628.782794.73
Upgrade
PB Ratio
4.651.00-4.358.27171.49898.54
Upgrade
P/TBV Ratio
8.70--22.11491.624534.72
Upgrade
EV/Sales Ratio
33.45-2.8728.36624.032796.40
Upgrade
Debt / Equity Ratio
0.070.26-1.981.530.060.06
Upgrade
Asset Turnover
0.010.070.320.090.170.13
Upgrade
Inventory Turnover
--896.212444.832074.0568.56
Upgrade
Quick Ratio
1.371.640.682.991.530.39
Upgrade
Current Ratio
1.421.820.743.111.711.46
Upgrade
Return on Equity (ROE)
-42.52%--684.77%-354.08%-282.65%-77.66%
Upgrade
Return on Assets (ROA)
-30.64%-53.91%-32.95%-82.82%-74.02%-22.32%
Upgrade
Return on Capital (ROIC)
-95.33%-146.88%-54.11%-121.58%-122.42%-55.00%
Upgrade
Earnings Yield
-7.67%-432.43%-87.80%-44.19%-1.51%-0.09%
Upgrade
FCF Yield
-34.70%-422.75%-56.58%-37.19%-0.96%-0.10%
Upgrade
Buyback Yield / Dilution
-2315.84%-608.45%-8.32%-41.86%-28.53%-64.39%
Upgrade
Total Shareholder Return
-2315.84%-608.45%-8.32%-41.86%-28.53%-64.39%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.